Ansari M - Search Results

1

DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia.

Al-Shakfa F, Dulucq S, Brukner I, Milacic I, Ansari M, Beaulieu P, Moghrabi A, Laverdière C, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajinovic M. Al-Shakfa F, et al. Among authors: ansari m. Clin Cancer Res. 2009 Nov 15;15(22):6931-8. doi: 10.1158/1078-0432.CCR-09-0641. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861437

2

Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.

Ansari M, Krajinovic M. Ansari M, et al. Curr Opin Pediatr. 2007 Feb;19(1):15-22. doi: 10.1097/MOP.0b013e3280140613. Curr Opin Pediatr. 2007. PMID: 17224657 Review.

3

[Pharmacogenomics of acute lymphoblastic leukemia].

Ansari M, St-Onge G, Krajinovic M. Ansari M, et al. Med Sci (Paris). 2007 Nov;23(11):961-7. doi: 10.1051/medsci/20072311961. Med Sci (Paris). 2007. PMID: 18021708 Free article. French.

4

DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL.

Dulucq S, St-Onge G, Gagné V, Ansari M, Sinnett D, Labuda D, Moghrabi A, Krajinovic M. Dulucq S, et al. Among authors: ansari m. Blood. 2008 Apr 1;111(7):3692-700. doi: 10.1182/blood-2007-09-110593. Epub 2007 Dec 20. Blood. 2008. PMID: 18096764 Free article.

5

Pharmacogenomics of acute leukemia.

Ansari M, Krajinovic M. Ansari M, et al. Pharmacogenomics. 2007 Jul;8(7):817-34. doi: 10.2217/14622416.8.7.817. Pharmacogenomics. 2007. PMID: 18240908 Review.

6

Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia.

Ansari M, Sauty G, Labuda M, Gagné V, Laverdière C, Moghrabi A, Sinnett D, Krajinovic M. Ansari M, et al. Blood. 2009 Aug 13;114(7):1383-6. doi: 10.1182/blood-2008-11-191098. Epub 2009 Jun 10. Blood. 2009. PMID: 19515727 Free article.

7

Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?

Ansari M, Krajinovic M. Ansari M, et al. Pharmacogenomics. 2009 Nov;10(11):1729-32. doi: 10.2217/pgs.09.135. Pharmacogenomics. 2009. PMID: 19891548 No abstract available.

8

Transcriptional regulation of CYP2C19 and its role in altered enzyme activity.

Uppugunduri CR, Daali Y, Desmeules J, Dayer P, Krajinovic M, Ansari M. Uppugunduri CR, et al. Among authors: ansari m. Curr Drug Metab. 2012 Oct;13(8):1196-204. doi: 10.2174/138920012802850146. Curr Drug Metab. 2012. PMID: 22804232 Review.

9

The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children.

Ansari M, Uppugunduri CR, Ferrari-Lacraz S, Bittencourt H, Gumy-Pause F, Chalandon Y, Tiercy JM, Schechter T, Gassas A, Doyle JD, Dupuis L, Duval M, Krajinovic M, Villard J. Ansari M, et al. PLoS One. 2013 Aug 19;8(8):e72141. doi: 10.1371/journal.pone.0072141. eCollection 2013. PLoS One. 2013. PMID: 23977232 Free PMC article.

10

Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation.

Ansari M, Théoret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, Vachon MF, Champagne MA, Duval M, Krajinovic M, Bittencourt H; Pediatric Disease Working Parties of the European Blood and Marrow Transplant Group. Ansari M, et al. Ther Drug Monit. 2014 Feb;36(1):93-9. doi: 10.1097/FTD.0b013e3182a04fc7. Ther Drug Monit. 2014. PMID: 24061446

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,593 results

Search Page

Filters